Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
about
Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideUnderlying Pathophysiology of HCV Infection in HIV-Positive Drug UsersStructure and mechanism of the complex between cytochrome P4503A4 and ritonavirIndividualization of antiretroviral therapy--pharmacogenomic aspectTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityABT-378, a highly potent inhibitor of the human immunodeficiency virus proteaseEffect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitorPharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administrationMultidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patientsPharmacokinetic interaction between ritonavir and indinavir in healthy volunteersEffect of fluoxetine on pharmacokinetics of ritonavir.Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment.Use of lopinavir/ritonavir associated with ergotamine resulting in foot amputation: brief communication.Coprescription of tamoxifen and medications that inhibit CYP2D6.Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.Modelling species selectivity in rat and human cytochrome P450 2D enzymesPharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavirIdentification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactionsPharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjectsTarget repurposing for neglected diseases.Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.Metabolomic screening and identification of the bioactivation pathways of ritonavirEffect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in manDevelopment and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patientsUse of antineoplastic agents in patients with cancer who have HIV/AIDS.Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanismTargeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose-insulin homeostasis in animal models.Untreated HIV infection is associated with higher blood alcohol levels.Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers.
P2860
Q24622161-D0FC238D-61B2-45D8-B34E-C61B86D40EFEQ27489073-DE5782A8-300A-4D5C-8599-05A00EDABCAFQ27664974-FBA7C181-BF3B-4E8F-815E-5121EDC1F37FQ28070574-5CD914B8-B7BA-4BDA-865B-96A56D7AAC2CQ28087473-FC993ACC-E7F1-43DC-92FA-C058BA82A0C1Q28369297-0B1BCCD6-111C-4A33-815F-6FD553BB45CEQ28552201-9A67A27B-FDAE-4D10-ADB3-DD5FBD48C0F6Q33435327-26920A16-EE59-4F50-B036-8189E3393257Q33692808-FD7C9F27-FC0D-475F-8C3D-6BBEDA61727CQ33694387-AB32F9AC-F6B8-4953-B202-893A013ADA78Q33700538-E41276A8-6CEC-4625-844C-82AF8643C4DDQ33702785-3C10F636-0723-4315-9DEA-379F73A5A520Q33839294-64EB4DC8-6F2E-477A-98AE-CD127BA65802Q33859722-4CF7AE7D-8E1D-4B6B-B6F6-54789540DE1DQ33898184-0AD832D0-ABD7-456C-8F94-7DBCEA8DEBE8Q34113462-4A50CD81-FE11-4A7E-A6A0-335E1D89CFB6Q34228277-C7B2A4C1-AC32-433C-AA70-54A010F03D5FQ34437996-B1D0B716-B4A1-4B15-ACD7-820F6D646442Q34596668-E84B5892-C530-4803-8E28-60EADD466FF3Q34720072-81496CDE-E10E-4CA4-8FD7-D06CA332ED3CQ34730244-0D67D529-A4E2-4126-B1BA-32E10F2A272DQ34936881-385618CF-5969-46E6-9BEB-A394BF0B6897Q35002453-D50199A9-A184-489B-AC55-238D1B470E4FQ35042153-6682EC56-35B7-4118-A842-9C6354509D0DQ35134071-C80B277F-6076-4BC4-A08C-BB0CF0F2CA11Q35135626-8507FE02-7DC3-44B0-A155-9AB7F396AC34Q35178447-6C33650B-7A19-4FBF-A8F7-DD49D662B79CQ35579558-1972352C-78AB-4C01-A865-68378AA5DE18Q35626853-1647B2EA-2C40-463F-A47D-48C662F655EBQ35802558-5FB5D3D9-0B16-4673-8A35-D012B2BA2669Q35803002-6804C647-7386-473D-A1D8-D309E0F24AA1Q35826686-B74886E4-9CC6-434E-92A7-EEE3F64569D3Q35932561-F9ADDF6B-14D9-4215-946D-37E09ADECB65Q35933538-6A9DFF80-6316-4B9F-91DB-74112BE580D7Q36040272-44377AFD-A871-4266-A1FC-252248B4FC24Q36320322-A567930D-7507-4504-B39F-1AC7ED22F7E3Q36390277-80BE28E2-D155-4944-8E02-B66678748BA7Q36890380-627846A4-61B3-448E-A77C-C16A03672EC6Q37045314-594F8430-1E3F-43B8-A53B-BA382C8D345FQ37072082-D440F488-E28A-40D4-892A-E5A37DBDD242
P2860
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.
description
1996 nî lūn-bûn
@nan
1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@ast
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@en
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir
@nl
type
label
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@ast
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@en
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir
@nl
prefLabel
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@ast
Cytochrome P450-mediated metab ...... 38) in human liver microsomes.
@en
Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir
@nl
P2093
P1476
Cytochrome P450-mediated metab ...... 538) in human liver microsomes
@en
P2093
P304
P407
P577
1996-04-01T00:00:00Z